Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2013 06:30 ET | Source: Coronado Biosciences

Coronado Biosciences Announces Independent Data Monitoring Committee Recommendation to Discontinue Falk Phase 2 Trial of TSO in Crohn's Disease

BURLINGTON, Mass., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
November 06, 2013 06:30 ET | Source: Coronado Biosciences

Coronado Biosciences Announces Personnel Realignment, Including Appointment of Kevin Horgan, M.D., as Chief Medical Officer

BURLINGTON, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
November 01, 2013 08:00 ET | Source: Coronado Biosciences

Coronado Biosciences Reports Financial Results for the Third Quarter Ended September 30, 2013

BURLINGTON, Mass., Nov. 1, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
October 14, 2013 08:30 ET | Source: Coronado Biosciences

Coronado Biosciences Announces Top-Line Results From Its TRUST-I Phase 2 Clinical Trial of TSO for the Treatment of Crohn's Disease

BURLINGTON, Mass., Oct. 14, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
September 12, 2013 07:30 ET | Source: Coronado Biosciences

Coronado Biosciences Announces Initiation of Phase 2 Study Evaluating TSO in Ulcerative Colitis

BURLINGTON, Mass., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
September 03, 2013 08:30 ET | Source: Coronado Biosciences

Coronado Biosciences to Present at Upcoming Healthcare Investor Conferences

BURLINGTON, Mass., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
August 27, 2013 08:30 ET | Source: Coronado Biosciences

Coronado Biosciences to Participate in Citi's 8th Annual Biotech Conference

BURLINGTON, Mass., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
August 20, 2013 08:30 ET | Source: Coronado Biosciences

Coronado Biosciences to Present at the Upcoming Themes in Helminth Biology Scientific Conference

BURLINGTON, Mass., Aug. 20, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
August 05, 2013 07:00 ET | Source: Coronado Biosciences

Coronado Biosciences Reports Financial Results for the Second Quarter Ended June 30, 2013

BURLINGTON, Mass., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
August 01, 2013 08:30 ET | Source: Coronado Biosciences

Coronado Biosciences to Present at Upcoming Healthcare Investor Conferences

BURLINGTON, Mass., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...